These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 36371186)

  • 1. SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases.
    Li Y; Yang X; Zhu W; Xu Y; Ma J; He C; Wang F
    Cancer Cell Int; 2022 Nov; 22(1):347. PubMed ID: 36371186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
    Botta GP; Kato S; Patel H; Fanta P; Lee S; Okamura R; Kurzrock R
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34375311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: A systematic review and meta-analysis.
    Wang N; Qin Y; Du F; Wang X; Song C
    Gene; 2022 Aug; 834():146638. PubMed ID: 35680019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes.
    Huang SC; Ng KF; Chang IY; Chang CJ; Chao YC; Chang SC; Chen MC; Yeh TS; Chen TC
    PLoS One; 2021; 16(1):e0245356. PubMed ID: 33481850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer.
    Chang G; Li W; Bai H; Duan J; Wang Z; Du X; Yu R; Wang Y; Wang M; Zhu Y; Zhang X; Li L; Wan R; Wang J
    Thorac Cancer; 2022 Nov; 13(21):2951-2959. PubMed ID: 36126963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
    Akinjiyan FA; Nassief G; Phillipps J; Adeyelu T; Elliott A; Abdulla F; Zhou AY; Souroullas G; Kim KB; Vanderwalde A; Park SJ; Ansstas G
    Sci Rep; 2024 Feb; 14(1):3444. PubMed ID: 38341515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
    Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
    Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Zhu G; Shi R; Li Y; Zhang Z; Xu S; Chen C; Cao P; Zhang H; Liu M; Pan Z; Liu H; Chen J
    Front Immunol; 2021; 12():670040. PubMed ID: 34512623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors' therapeutic implication.
    Pang LL; Zhou HQ; Zhang YX; Zhuang WT; Pang F; Chen LJ; Liao J; Huang YH; Mao TQ; Mai ZH; Zhang L; Fang WF
    ESMO Open; 2024 Jun; 9(6):103472. PubMed ID: 38833972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational landscape of SWI/SNF complex genes reveal correlation to predictive biomarkers for immunotherapy sensitivity in lung adenocarcinoma patients.
    Xu H; Chen HC; Yang L; Yang G; Liang L; Yang Y; Tang H; Bao H; Wu X; Shao Y; An G; Wang Y
    ESMO Open; 2023 Jun; 8(3):101585. PubMed ID: 37327699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
    Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
    Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
    Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L
    Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
    Tokunaga R; Xiu J; Goldberg RM; Philip PA; Seeber A; Battaglin F; Arai H; Lo JH; Naseem M; Puccini A; Berger MD; Soni S; Zhang W; Chen S; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Eur J Cancer; 2020 Nov; 140():119-129. PubMed ID: 33080474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
    Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
    Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SWI/SNF Complex Genomic Alterations as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Multiple Cancers.
    Wang D; Wang J; Zhou D; Wu Z; Liu W; Chen Y; Chen G; Zhang J
    Cancer Immunol Res; 2023 May; 11(5):646-656. PubMed ID: 36848524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large-Scale Cancer Genomic Analysis Reveals Significant Disparities between Microsatellite Instability and Tumor Mutational Burden.
    Choi J; Park KH; Kim YH; Sa JK; Sung HJ; Chen YW; Chen Z; Li C; Wen W; Zhang Q; Shu XO; Zheng W; Kim JS; Guo X
    Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):712-720. PubMed ID: 38393316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.